Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.32 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3100801 | 0.92 | TRPV4 (0.39) | TRPV4MAOAMAOBARRAD51 | |
| SCHEMBL721330 | 0.81 | TRPV4 (0.43) | TRPV4MAOAMAOBARRAD51 | |
| SCHEMBL13157445 | 0.80 | TSHR (0.45) | TRPV4MEN1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL13157381 | 0.79 | CNR1 (0.40) | TRPV4KMT2ACYP3A4MAPTCNR1 | |
| SCHEMBL2823894 | 0.79 | USP2 (0.48) | TRPV4MEN1KMT2ACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL2822124 | 0.78 | USP2 (0.47) | TRPV4MEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL13157384 | 0.78 | CNR1 (0.41) | TRPV4KMT2ACNR1 | |
| SCHEMBL1279059 | 0.78 | L3MBTL1 (0.44) | TRPV4MEN1KMT2AMAPTHPGD | |
| Bromide SCHEMBL1279761 | 0.77 | L3MBTL1 (0.43) | TRPV4MEN1KMT2ACYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL1279717 | 0.77 | L3MBTL1 (0.43) | TRPV4MEN1KMT2AMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2749554-B1 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | SMA THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-2749554-B1 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | SMA THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9187425-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187425-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187425-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2749554-A2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2749554-A2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | Axikin Pharmaceuticals, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| US-8563544-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130065889-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065889-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130065889-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8318747-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318747-B2 | 2,5-disubstituted arylsulfonamide CCR3 antagonists | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2421830-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010123959-A2 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273785-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273785-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031841-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | TRPV4 991/4885MAOA 4704/4885MAOB 4269/4885 |
| US-20100273785-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | TRPV4 1657/4885MAOA 4583/4885MAOB 3900/4885 |
| US-20130065889-A1 | 2,5-DISUBSTITUTED ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | TRPV4 991/4885MAOA 4704/4885MAOB 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.